<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01540162</url>
  </required_header>
  <id_info>
    <org_study_id>NIS MU 1128 AO</org_study_id>
    <nct_id>NCT01540162</nct_id>
  </id_info>
  <brief_title>Experience of Mutaflor Suspension Use in Preterm Infants for Immunity Improvement</brief_title>
  <acronym>EMSUP</acronym>
  <official_title>Open-labelled, Controlled, Parallel Group Study to Assess the Efficacy and Safety of MUTAFLOR in 3 Weeks Treatment for Immunity Improvement in Preterm Infants With 1 Year Follow-up Period</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Odessa National Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Odessa National Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      EcN has been registered as a medical drug under the brand name Mutaflor® SUSPENSION in
      Ukraine in 2010. Indications for its clinical use are acute diarrhea in infants and toddlers
      including those on tube feeding tube, diarrhea in children, prophylactics of pathological
      colonization in newborns including premature newborns, and improvement of immunity in
      newborns (mature and premature).

      The aim of this trial was to observe efficacy and safety of Mutaflor® SUSPENSION use for
      immunity improvement in preterm newborn infants
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study design: open-labeled, controlled, parallel group, non-interventional 3-weeks-study with
      followed prospective observation during 1 week and 1 year follow-up period.

      Patients of group I take the probiotic Mutaflor orally in the dose 1 ml once a day during
      first week of life and three times per week during the second and third week of life.
      Patients of the group II don't take specific probiotic for immunity strengthening.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The Number (Rate) of Patients With Acute Respiratory Infections</measure>
    <time_frame>first 28 days of life</time_frame>
    <description>ARI: Acute Rhinitis, Acute Rhinopharyngitis, Acute Bronchitis, Acute Bronchiolitis and Pneumonia</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Number (Rate) of Patients With Acute Respiratory Infections</measure>
    <time_frame>first 6 month of life</time_frame>
    <description>ARI: Acute Rhinitis, Acute Rhinopharyngitis, Acute Bronchitis, Acute Bronchiolitis and Pneumonia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number (Rate) of Patients With Acute Respiratory Infections</measure>
    <time_frame>first 12 month of life</time_frame>
    <description>ARI: Acute Rhinitis, Acute Rhinopharyngitis, Acute Bronchitis, Acute Bronchiolitis and Pneumonia</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">62</enrollment>
  <condition>Neonatal Infection</condition>
  <arm_group>
    <arm_group_label>Group I</arm_group_label>
    <description>Patients of group I are exposed to the probiotic Mutaflor: 1 ml once a day during first week of life, and three times per week during the second and third week of life.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group II</arm_group_label>
    <description>Patients of group II remain unexposed to the probiotic Mutaflor.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Preterm newborns with gestational age of 35-36 weeks
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 12-24 hours of life;

          -  1st degree of prematurity (functionally mature infant, gestational age 35-36 weeks);

          -  exclusive breast feeding during study;

          -  both parents must sign and date an informed consent for infant's participation in the
             study.

        Exclusion Criteria:

          -  perinatal asphyxia ( Apgar score less than 8);

          -  significant concomitant disease (congenital birth defects, perinatal encephalopathy,
             TORCH - infections and other infectious disease of newborn, respiratory distress
             syndrome ets);

          -  clinically significant changes in blood analyze results (if needed);

          -  use of other probiotics or prebiotics during the first 28 days of study participation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>24 Hours</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mykola L Aryayev, Prof MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Odessa National Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maternity House №5</name>
      <address>
        <city>Odessa</city>
        <zip>650000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Ukraine</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 16, 2012</study_first_submitted>
  <study_first_submitted_qc>February 22, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 28, 2012</study_first_posted>
  <results_first_submitted>August 12, 2015</results_first_submitted>
  <results_first_submitted_qc>August 12, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 10, 2015</results_first_posted>
  <last_update_submitted>August 12, 2015</last_update_submitted>
  <last_update_submitted_qc>August 12, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Odessa National Medical University</investigator_affiliation>
    <investigator_full_name>Mykola L Aryayev, MD PhD</investigator_full_name>
    <investigator_title>Professor, MD, PhD</investigator_title>
  </responsible_party>
  <keyword>preterm newborn</keyword>
  <keyword>neonatology</keyword>
  <keyword>EcN</keyword>
  <keyword>Nissle</keyword>
  <keyword>Mutaflor</keyword>
  <keyword>prophylaxis</keyword>
  <keyword>infection</keyword>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Group I</title>
          <description>Patients of group I are exposed to the probiotic Mutaflor: 1 ml once a day during first week of life, and three times per week during the second and third week of life.</description>
        </group>
        <group group_id="P2">
          <title>Group II</title>
          <description>Patients of group II remain unexposed to the probiotic Mutaflor.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group I</title>
          <description>Patients of group I are exposed to the probiotic Mutaflor: 1 ml once a day during first week of life, and three times per week during the second and third week of life.</description>
        </group>
        <group group_id="B2">
          <title>Group II</title>
          <description>Patients of group II remain unexposed to the probiotic Mutaflor.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="32"/>
            <count group_id="B3" value="62"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Newborns</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Ukraine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Number (Rate) of Patients With Acute Respiratory Infections</title>
        <description>ARI: Acute Rhinitis, Acute Rhinopharyngitis, Acute Bronchitis, Acute Bronchiolitis and Pneumonia</description>
        <time_frame>first 28 days of life</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group I</title>
            <description>Patients of group I are exposed to the probiotic Mutaflor: 1 ml once a day during first week of life, and three times per week during the second and third week of life.</description>
          </group>
          <group group_id="O2">
            <title>Group II</title>
            <description>Patients of group II remain unexposed to the probiotic Mutaflor.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number (Rate) of Patients With Acute Respiratory Infections</title>
          <description>ARI: Acute Rhinitis, Acute Rhinopharyngitis, Acute Bronchitis, Acute Bronchiolitis and Pneumonia</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.05</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.05</ci_lower_limit>
            <ci_upper_limit>0.73</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number (Rate) of Patients With Acute Respiratory Infections</title>
        <description>ARI: Acute Rhinitis, Acute Rhinopharyngitis, Acute Bronchitis, Acute Bronchiolitis and Pneumonia</description>
        <time_frame>first 6 month of life</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group I</title>
            <description>Patients of group I are exposed to the probiotic Mutaflor: 1 ml once a day during first week of life, and three times per week during the second and third week of life.</description>
          </group>
          <group group_id="O2">
            <title>Group II</title>
            <description>Patients of group II remain unexposed to the probiotic Mutaflor.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number (Rate) of Patients With Acute Respiratory Infections</title>
          <description>ARI: Acute Rhinitis, Acute Rhinopharyngitis, Acute Bronchitis, Acute Bronchiolitis and Pneumonia</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number (Rate) of Patients With Acute Respiratory Infections</title>
        <description>ARI: Acute Rhinitis, Acute Rhinopharyngitis, Acute Bronchitis, Acute Bronchiolitis and Pneumonia</description>
        <time_frame>first 12 month of life</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group I</title>
            <description>Patients of group I are exposed to the probiotic Mutaflor: 1 ml once a day during first week of life, and three times per week during the second and third week of life.</description>
          </group>
          <group group_id="O2">
            <title>Group II</title>
            <description>Patients of group II remain unexposed to the probiotic Mutaflor.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number (Rate) of Patients With Acute Respiratory Infections</title>
          <description>ARI: Acute Rhinitis, Acute Rhinopharyngitis, Acute Bronchitis, Acute Bronchiolitis and Pneumonia</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Group I</title>
          <description>Patients of group I are exposed to the probiotic Mutaflor: 1 ml once a day during first week of life, and three times per week during the second and third week of life.</description>
        </group>
        <group group_id="E2">
          <title>Group II</title>
          <description>Patients of group II remain unexposed to the probiotic Mutaflor.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acute Respiratory and Gastrointestinal Infections</sub_title>
                <description>Hospitalisation due to ARIs and GIs</description>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="30"/>
                <counts group_id="E2" events="22" subjects_affected="20" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Changed Blood Parameter</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal disorders</sub_title>
                <description>infant colic, acute enterocolitis, constipation, regurgitation, diarrhoea</description>
                <counts group_id="E1" events="14" subjects_affected="12" subjects_at_risk="30"/>
                <counts group_id="E2" events="14" subjects_affected="13" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Respiratory Infections</sub_title>
                <description>acute rhinitis, acute rhinopharyngitis, acute bronchitis</description>
                <counts group_id="E1" events="17" subjects_affected="15" subjects_at_risk="30"/>
                <counts group_id="E2" events="24" subjects_affected="22" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>dermatitis</sub_title>
                <description>diaper dermatitis, atopic dermatitis</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Prof. Mykola L. Aryayev, MD &amp; PhD</name_or_title>
      <organization>National Medical University Odessa</organization>
      <phone>+380 48 740 5249</phone>
      <email>nataly_kononenko@ukr.net</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

